Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARES Study: Tumor-infiltrating lymphocyte (TIL) therapy in refractory germ cell tumors
2025-522427-10-00Phase 2Authorised
- Sponsor
- Bellvitge Institute for Biomedical Research
- Start
- Nov 2025
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous tumor-infiltrating lymphocytes in germ cell tumor (GCT), sponsored by Bellvitge Institute for Biomedical Research. Primary endpoint: Favorable response rate. Planned start Nov 2025; status: authorised.
02
Drugs
autologous tumor-infiltrating lymphocytes
03
Conditions
germ cell tumor (GCT)
Beyond the preview
Go deeper on 2025-522427-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522427-10-00.